HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA nanotech meeting

This article was originally published in The Rose Sheet

Executive Summary

Agency will sponsor public meeting in mid-October on nanotechnology, FDA announces in April 13 Federal Register notice. Topics slated to be discussed include types of nanotechnology material products under development in the areas of cosmetics, foods, drugs and other FDA-regulated areas. Meeting also provides opportunity to evaluate "whether there are scientific issues that should be addressed; and any other issues about which the regulated industry, academia and the interested public may wish to inform FDA" concerning nanotechnology use, FDA notes. Details regarding date and time of meeting, which will be held in Washington, D.C., will be provided in a subsequent Federal Register notice, agency adds...

You may also be interested in...



FDA nanotech meeting

Pre-registration for the Oct. 10 Nanotechnology Task Force public meeting on nanotechnology closed Sept. 29, however, there will be on-site registration on a first-come, first-served basis until the room capacity is reached, FDA announces in a Sept. 26 Federal Register 1notice. The meeting, which will address the types of nanotechnology material products under development in the areas of foods, drugs and cosmetics, will be held in the Natcher Auditorium at the National Institutes of Health campus in Bethesda, Md. FDA announced plans for the meeting in April (2"The Rose Sheet" April 17, 2006, In Brief)...

FDA Forms Nanotechnology Task Force To Assess Technology

FDA's Nanotechnology Task Force will identify policy gaps related to the use of nanotechnology particles to evaluate possible adverse health effects from products that contain the materials, the agency said

Nanomaterial Sunscreens Should Be Designated “New Drugs” – Petition

FDA should amend the OTC final sunscreen monograph to specify that products containing engineered nanoparticles are excluded and designate the formulas "new drugs," a coalition of public interest groups states in a citizen petition
UsernamePublicRestriction

Register

RS013864

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel